Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?

Annals of Surgical Oncology

Volumn 13, Issue 11, 2006, Pages 1379-1385

  Suh, Kwang Wook ^a   Kim, Joo Hyung ^a   Kim, Do Yoon ^a   Kim, Young Bae ^a   Lee, Chulho ^b   Choi, Sungho ^b  

^a Ajou University School of Medicine   (South Korea)

^b ABIXIS Co Ltd   (South Korea)

Author keywords

FOLFOX XRCC1 MTHFR; Gene polymorphism; Metastatic colon cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; FLUOROURACIL; FOLFOX PROTOCOL; FOLINIC ACID; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PLATINUM COMPLEX; X RAY REPAIR CROSS COMPLEMENTING PROTEIN 1; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

ADULT; AGED; ARTICLE; COLORECTAL TUMOR; COMPARATIVE STUDY; DOMINANT GENE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; KOREA; MALE; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; FLUOROURACIL; GENES, DOMINANT; GENOTYPE; HUMANS; KOREA; LEUCOVORIN; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 34848869833     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9112-y     Document Type: Article

References (29)

1. Okumura K, Shiomi H, Mekata E, Kaizuka M, Kurumi Y, Tani T. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer. Oncol Rep 2006; 15:875-882.
2. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Pharmacogenomics and clinical biomarkers in drug discovery and development. Am J Clin Pathol 2005; 124(Suppl):S29-41.
3. van Triest B, Pinedo HM, Blaauwgeers JL, et al. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet- derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 2000; 6:1063-1072. (Pubitemid 30159368)
4. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19:4298-4304. (Pubitemid 33096777)
5. Allen WL, Johnston PG. Role of genomic markers in colorectal cancer treatment. J Clin Oncol 2005; 23:4545-4552. (Pubitemid 46196585)
6. Yamayoshi Y, Iida E, Tanigawara Y. Cancer pharmacogenomics: international trends. Int J Clin Oncol 2005; 10:5-13. (Pubitemid 40379488)
7. Etienne MC, Formento JL, Chazal M, et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004; 14:785-792. (Pubitemid 40054334)
8. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz H-J. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91:344-354. (Pubitemid 39037082)
9. Suh KW, Kim JH, Kim YB, Kim J, Jeong S. Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer. J Gastrointest Surg 2005; 9:336-342. (Pubitemid 40327100)
10. Goldberg RM. Advances in the treatment of metastatic colorectal cancer. Oncologist 2005; 10(Suppl 3):40-48. (Pubitemid 43152729)
11. Saltz LB. Metastatic colorectal cancer: is there one standard approach?. Oncology 2005; 19:1147-1154. (Pubitemid 350042576)
12. de Gramont A, Figer A, Seymour M, et al. Leukovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947. (Pubitemid 30644117)
13. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leukovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30. (Pubitemid 41095110)
14. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leukovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-147. (Pubitemid 30036347)
15. Raymond E, Faivre S, Woynarowski JM, Chaney SG. mechanism of action and antineoplastic activity. Semin Oncol 1998; 25:4-12.
16. Cohen V, Raymond VP, Sabbaghian N, Morin I, Batist G, Rozen R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9:1611-1615. (Pubitemid 36554583)
17. Stoehlmacher J, Ghaderi V, Iqval S, Groshen S, Tsao-wei D, Park D, Lenz HJ. A polymorphsim of xrcc1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001; 21:3075-3080.
18. Scheele J, Stang R, Altendorf-Hofman A, Paul M. Resection of colorectal liver metastasis. World J Surg 1995; 19:59-71.
19. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999; 230:309-321. (Pubitemid 30191861)
20. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J Clin Oncol 2005; 23:4553-4560. (Pubitemid 46196586)
21. Balasubramanian SP, Cox A, Brown NJ, Reed MW. Candidate gene polymorphism in solid cancers. Eur J Surg Oncol 2004; 30:593-601. (Pubitemid 39060727)
22. Liu Z, Lin S. Multilocus LD measure and tagging SNP selection with generalized mutual information. Genet Epidemiol 2005; 29:353-364. (Pubitemid 41720953)
23. Sanguedolce R, Vultaggio G, Sanguedolce F, et al. The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res 1998; 18:1515-1520. (Pubitemid 28342553)
24. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumor responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6:1322-1327. (Pubitemid 30226214)
25. Little J, Sharp L, Duthie S, Narayanan S. Colon cancer and genetic variation in folate metabolism: the clinical bottom line. J Nutr 2003; 133[Suppl 11]:3758-66s.
26. Curtin K, Bigler J, Slattery ML, Caan B, Potter JD, Ulrich CM. MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 2004; 13:285-92. (Pubitemid 38222562)
27. Mani RS, Karimi-Busher F, Fanta M, Caldecott KW, Cass CE, Weinfield M. Biophysical characterization of human XRCC1 and its binding to damaged and undamaged DNA. Biochemistry 2004; 43:16505-14. (Pubitemid 40041063)
28. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia JM, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 1998; 18:3563-3571. (Pubitemid 28240528)
29. de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997; 94:7303-7307. (Pubitemid 27345310)